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In human washed platelets, collagen-induced phosphoinositide turnover was inhibited by indomethacin, an 
inhibitor of thromboxane A, (TXAJ formation, particularly at lower doses of collagen. This inhibition was 
counteracted by the addition of 9,1 I-epithio-1 1,12-methano-TXA, (STAJ, a stable analogue of TXA, as 
well as by the Ca *+ ionophore A23187. STA, and A23187 did not stimulate phosphoinositide turnover 
markedly, but significantly increased cytoplasmic free CaZ+ concentrations. The actions of STA, were 
blocked by 13-azaprostanoic acid, a TXA, receptor antagonist. These results suggest hat TXA, is generated 
during the action of collagen and increases cytoplasmic free Ca2+ which then stimulates phosphoinositide 
turnover in cooperation with collagen. 
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1. INTRODUCTION 
Collagen induces both secretion and aggregation 
in human platelets [l]. These reactions induced by 
collagen are inhibited by indomethacin or aspirin 
which are known to inhibit collagen-induced 
generation of PGG2, PGH2 and TXA2 [2,3]. These 
arachidonic acid metabolites have been shown to 
induce secretion and aggregation [2,3]. Based on 
these observations, it has been suggested that 
PGH2 and TXA2 may play a role of crucial impor- 
tance in the action of collagen [2-61. Another line 
of evidence indicates that collagen induces 
phosphoinositide turnover and Ca2+ mobilization, 
which are involved in the secretory processes 
through the activation of protein kinase C and 
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Abbreviations: PG, prostaglandin; TX, thromboxane; 
=-AZ, 9,ll -epithio-1 1,12-methanothromboxane AZ; 
MLC, myosin light chain; PA, phosphatidic acid; IP3, 
inositol 1,4,Strisphosphate 
calmodulin, respectively [6-81. Rittenhouse and 
Allen [4] have shown that PGH2 and its stable 
analogue U46619 induce phosphoinositide turn- 
over to a small extent but counteract the inhibition 
by aspirin of collagen-induced phosphoinositide 
turnover. 
A preceding report from our laboratory has 
described that STA2, a stable analogue of TXA2, 
increases cytoplasmic free Ca2+ concentrations [9]. 
During the course of studies on the mode of action 
of STA2, we have clarified that STA2 by itself does 
not induce phosphoinositide turnover to a great ex- 
tent but enhances this reaction induced by collagen 
in the platelets pretreated with indomethacin. 
Moreover, evidence has been obtained that this ac- 
tion of STA2 is replaced by the Ca2+ ionophore 
A23187. This paper describes a possible function 
of Ca 2t in the action of STA2 which enhances 
collagen-induced phosphoinositide turnover. 
Here, elevation of cytoplasmic free Ca2+ concen- 
trations was estimated by measuring the 
phosphorylation of MLC, since this protein 
phosphorylation is triggered by Ca2+ in proportion 
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to its increase through the activation of 
Ca’+-activated, calmodulin-dependent protein 
kinase [lO,ll]. 
2. MATERIALS AND METHODS 
2.1. Materials and chemicals 
STAz and 13-azaprostanoic acid were donated 
by Ono Pharmaceutical Co. Collagen and throm- 
bin were the products of Hormon-Chemie and 
Mochida Pharmaceutical, respectively. TXBz was 
obtained from Funakoshi Pharmaceutical. 
Carrier-free 32Pi and [3H]arachidonic acid 
(78.2 Ci/mmol) were purchased from Japan 
Radioisotope Association and New England 
Nuclear, respectively. Other materials and 
chemicals were obtained from commercial sources. 
2.2. Preparation of radioactive platelets 
Human washed platelets were prepared by the 
method of Mustard et al. [12]. Platelets were la- 
beled with 32Pi or [3H]arachidonic acid as de- 
scribed [6]. The radioactive washed platelets were 
finally suspended at 6 x IO* cells/ml in a Tyrode’s 
solution containing 128 mM NaCl, 2.7 mM KCl, 
12 mM NaHC03, 0.36 mM NaH2P04, 2 mM 
MgC12 and 5.5 mM glucose. 
2.3. Assay for phosphoinositide turnover 
Washed platelets prelabeled with 32Pi were 
stirred at 37°C in an aggregometer, and various 
drugs and stimuli were added as indicated in each 
experiment. The radioactive lipids were directly ex- 
tracted from the platelets by the method of Bligh 
and Dyer [13] and subjected to thin-layer chroma- 
tography as in [8]. The areas corresponding to PA 
were scraped off and the radioactivity was 
determined. 
2.4. Assay for A4LC phosphorylation 
Washed platelets prelabeled with 32Pi were in- 
cubated with various drugs and stimuli as de- 
scribed above. Radioactive platelet proteins were 
directly subjected to SDS slab gel electrophoresis, 
stained, dried on filter paper, and then exposed to 
an X-ray film to prepare an autoradiograph as 
described [6]. Electrophoresis was carried out by 
the method of Laemmli [ 141. The relative intensity 
of each band was quantitated by densitometric 
tracing of the autoradiograph using a Shimadzu 
model CS-910 dual-wavelength chromatogram 
scanner. 
2.5. Analysis of TXB2 formation 
Washed platelets prelabeled with [3H]arachidon- 
ic acid were incubated with various drugs and 
stimuli as described above, and the reaction was 
terminated by the addition of formic acid. Radio- 
active arachidonic acid metabolites were analyzed 
by the method of Needleman et al. [ 151. TXB2 was 
identified by an authentic marker and its radioac- 
tivity was determined. 
3. RESULTS 
As shown in fig. 1, collagen stimulated 32P incor- 
poration into PA and MLC phosphorylation in a 
parallel manner. These reactions induced by col- 
lagen were markedly inhibited by preincubation of 
platelets with indomethacin. Such inhibitory ef- 
fects of indomethacin were more prominent at 
---I- 
B 1 
Fig. 1. Inhibition by indomethacin of collagen-induced 
32P incorporation into PA and MLC phosphorylation in 
platelets. The platelets prelabeled with 32P, were 
incubated with indomethacin (5 gg/ml) for 2 min at 
37”C, and then stimulated by various doses of collagen 
for 1.5 min at 37°C as indicated. Other details are 
described in section 2. The basal levels of 32P 
incorporation into PA and MLC phosphorylation were 
320 cpm and 0.04 A units at 430 nm, respectively. These 
values were subtracted from experimental values. 
Results are presented as the average of an experiment 
performed in triplicate. (A) 32P incorporation into PA, 
(B) MLC phosphorylation. (o--o) In the absence of 
indomethacin, (O---O) in the presence of indomethacin. 
105 
Volume 192, number 1 FEBS LETTERS November 1985 
lower doses of collagen. Under similar conditions, 
indomethacin completely blocked the generation 
of TXAz as measured by the formation of TXB2, 
a stable inactive metabolite of TXA2 (not shown). 
These results are in good agreement with earlier 
observations [4-61 and suggest that arachidonic 
acid metabolites such as TXA2 may be involved in 
collagen-induced 32P incorporation into PA and 
MLC phosphorylation. 
Table 1 shows that STA2 elicited sufficiently 
MLC phosphorylation but stimulated 32P incor- 
poration into PA to a small extent. However, this 
TXA2 analogue overcame the inhibitory effect of 
indomethacin upon collagen-induced 32P incor- 
poration into PA as shown in table 1. Moreover, 
the simultaneous addition of STA2 and collagen to 
the platelets pretreated with indomethacin 
Table 1 
Counteraction by STA2 of inhibitory effects of 
indomethacin on collagen-induced “P incorporation 
into PA and MLC phosphorylation 
Additions 32P in- MLC phos- 
corporation phorylation 
into PA (A at 
(cpm) 430 nm) 
None 0 0.00 
STA2 690 0.12 
STA2 + indomethacin 610 0.12 
Indomethacin 10 0.00 
Collagen (12.5 ag/ml) 1950 0.15 
+ indomethacin 350 0.06 
+ indomethacin + STA2 2260 0.16 
+ STAz 2510 0.18 
Collagen (25 pg/ml) 2230 0.18 
+ indomethacin 1290 0.12 
+ indomethacin + STA2 3180 0.18 
+ STA2 3290 0.18 
Platelets prelabeled with “Pi were incubated with 
indomethacin (5 pg/ml) for 2 min at 37°C and then 
stimulated by collagen and STA2 (6 nM) for 1.5 min at 
37°C as indicated. Other details are described in section 
2. The basal levels of 32P incorporation into PA and 
MLC phosphorylation were 320 cpm and 0.04 A units at 
430 nm, respectively. These values were subtracted from 
experimental values. Results are presented as the average 
of an experiment performed in triplicate 
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stimulated 32P incorporation into PA significantly 
more than the theoretical summation of this reac- 
tion which was induced by collagen plus in- 
domethacin and STA2 plus indomethacin. The 
potentiating effect of STA2 was more prominent at 
lower doses of collagen. STA2 and collagen 
stimulated only additively 32P incorporation into 
PA in the platelets which were not treated with in- 
domethacin. This might be due to the ability of 
collagen which by itself induced arachidonic acid 
mobilization and produced endogenous TXAz. 
These results are consistent with the earlier obser- 
vations made with PGH2 and U46619 [4]. Under 
the same conditions, STA2 also reversed the inhibi- 
Table 2 
Counteraction by A23187 of inhibitory effects of 
indomethacin on collagen-induced 32P incorporation 
into PA and MLC phosphorylation 
Additions 32P in- MLC phos- 
corporation phorylation 
into PA (A at 
(cpm) 430 nm) 
None 0 0.00 
A23187 130 0.19 
A23 187 + indomethacin 90 0.19 
Indomethacin 10 0.00 
Collagen (12.5 pg/ml) 1950 0.15 
+ indomethacin 350 0.06 
+ indomethacin + 
A23 187 1790 0.19 
+ A23187 1970 0.19 
Collagen (25 pg/ml) 2230 0.18 
+ indomethacin 1290 0.12 
+ indomethacin + 
A23187 2150 0.19 
+ A23187 2250 0.19 
Platelets prelabeled with “Pi were incubated with 
indomethacin (5 pg/ml) for 2 min at 37°C and then 
stimulated by collagen and A23187 (0.6 PM) for 1.5 min 
at 37°C as indicated. Other details are described in 
section 2. The basal levels of 32P incorporation into PA 
and MLC phosphorylation were 320 cpm and 0.04 A 
units at 430 nm, respectively. These values were 
subtracted from experimental values. Results are 
presented as the average of an experiment performed in 
triplicate 
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tion by indomethacin of collagen-induced MLC 
phosphorylation, but did not show synergistic ef- 
fects on this phosphorylation. These effects of 
STA2 were blocked by 13-azaprostanoic acid, 
which is an antagonist for a TXAz receptor [16] 
(not shown). 
In another set of experiments, we examined 
whether the Ca2+ ionophore A23187 is able to 
substitute for STA2 in the actions described above, 
since it has been described that A23 187 increases 
cytoplasmic free Ca2+ concentrations and induces 
much less phosphoinositide turnover than other 
agonists such as thrombin [17]. Consistent with 
this observation, A23187 by itself did not stimulate 
32P incorporation into PA but fully induced MLC 
phosphorylation as shown in table 2. Moreover, 
A23187 counteracted the inhibition by in- 
domethacin of collagen-induced 32P incorporation 
into PA and MLC phosphorylation. As in the case 
of STA2, A23187 and collagen synergistically 
enhanced 32P incorporation into PA in the 
platelets pretreated with indomethacin. However, 
A23187 and collagen stimulated this reaction only 
additively in the platelets which were not treated 
with indomethacin. Under the same conditions, 
A23 187 reversed the inhibition by indomethacin of 
collagen-induced MLC phosphorylation, but did 
not show synergistic effects on this phos- 
phorylation. 
4. DISCUSSION 
This paper clearly demonstrates that STAz in- 
creases cytoplasmic free Ca2+, as estimated by 
measuring the phosphorylation of MLC, without 
marked induction of phosphoinositide turnover, 
but significantly enhances this reaction induced by 
the agonist in the platelets pretreated with in- 
domethacin. Evidence is also presented that these 
actions of STAz are observed with Ca2+ ionophore 
A23187. These results strongly suggest hat these 
agents enhance collagen-induced phosphoinositide 
turnover through Ca2+ mobilization. Since the ac- 
tions of STA2 are inhibited by an antagonist for 
the TXA2 receptor, they are mediated through the 
TXA2 receptor. Presumably, TXA2 is generated 
during the action of collagen, increases 
cytoplasmic free Ca’+, and finally stimulates 
collagen-initiated phosphoinositide turnover. It is 
evident from our results as well as earlier observa- 
tions [4,17] that Ca2+ mobilization alone is not suf- 
ficient and the occupation of the receptor with col- 
lagen is absolutely necessary for the induction of 
phosphoinositide turnover. 
It has been described that thrombin-induced 
phosphoinositide turnover is initiated by the 
hydrolysis of phosphatidylinositol, phosphatidyl- 
inositol 4-phosphate and phosphatidylinositol 
4,5_bisphosphate by the action of phospholipase 
C, resulting in the production of diacylglycerol and 
respective phosphorylated inositols [4,6,18-221. 
Recent analysis has revealed that thrombin-in- 
duced IP3 production is independent of Ca2+ 
mobilization and IP3 serves as a messenger for 
Ca2+ mobilization from the dense tubular system 
to the cytoplasm [23]. Evidence is also available 
that thrombin-induced hydrolysis of phosphatidyl- 
inositol is stimulated by Ca2+ [ 11,241. Although it 
has not yet been demonstrated whether collagen 
and TXAZ may produce IP3, it is conceivable that 
TXAz may enhance collagen-induced hydrolysis of 
phosphatidylinositol and phosphatidylinositol 
4-phosphate through Ca2+ mobilization and 
thereby stimulate phosphoinositide turnover. The 
modes of action of the collagen receptor and Ca2+ 
on the activation of phospholipase C are now 
under investigation in our laboratory. 
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